01 10Inlyta
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 477
2018 Revenue in Millions : 298
Growth (%) : 60
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 787
2019 Revenue in Millions : 477
Growth (%) : 65
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,002
2020 Revenue in Millions : 787
Growth (%) : 27
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,003
2021 Revenue in Millions : 1,002
Growth (%) : 0
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,036
2022 Revenue in Millions : 1,003
Growth (%) : 3
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 28.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 410
2014 Revenue in Millions : 430
Growth (%) : 5%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 401
2015 Revenue in Millions : 430
Growth (%) : -7
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 339
2016 Revenue in Millions : 401
Growth (%) : -15
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 297
2017 Revenue in Millions : 339
Growth (%) : -12%
LOOKING FOR A SUPPLIER?